Exscientia (NASDAQ:EXAI) Hits New 52-Week Low at $4.13

Shares of Exscientia plc (NASDAQ:EXAI) hit a new 52-week low during trading on Wednesday . The stock traded as low as $4.13 and last traded at $4.16, with a volume of 213422 shares changing hands. The stock had previously closed at $4.38.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on EXAI shares. Bank of America downgraded shares of Exscientia from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $11.00 to $9.00 in a research report on Friday, January 5th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 price objective on shares of Exscientia in a research report on Monday.

Exscientia Trading Up 1.0 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22. The stock has a market capitalization of $487.19 million, a PE ratio of -2.72 and a beta of 0.78. The stock’s 50 day simple moving average is $5.63 and its two-hundred day simple moving average is $5.83.

Exscientia (NASDAQ:EXAI) last released its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The firm had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. On average, sell-side analysts expect that Exscientia plc will post -1.76 EPS for the current year.

Institutional Trading of Exscientia

A number of institutional investors have recently modified their holdings of EXAI. Platinum Investment Management Ltd. lifted its stake in shares of Exscientia by 10.2% during the 3rd quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company’s stock valued at $19,866,000 after buying an additional 405,426 shares in the last quarter. Banque Pictet & Cie SA purchased a new stake in Exscientia in the 3rd quarter worth approximately $1,040,000. Federated Hermes Inc. purchased a new stake in Exscientia in the 3rd quarter worth approximately $362,000. DekaBank Deutsche Girozentrale purchased a new stake in Exscientia in the 3rd quarter worth approximately $344,000. Finally, Jump Financial LLC purchased a new stake in Exscientia in the 3rd quarter worth approximately $165,000. 41.58% of the stock is currently owned by hedge funds and other institutional investors.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.